Urinary tract infections in patients with neurogenic bladder.

Bactéries multi-résistantes Infections urinaires Multidrug-resistant bacteria Neurogenic bladder Prevention Prévention Urinary tract infections Vessie neurologique

Journal

Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 02 05 2018
revised: 04 09 2018
accepted: 21 02 2019
pubmed: 20 3 2019
medline: 23 4 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

Urinary tract infections (UTIs) in patients with neurogenic bladder are a major public health issue due to their high incidence and major consequences. Despite their frequency and potential severity, their physiopathology and management are poorly known. We provide a narrative literature review on the epidemiology, physiopathology, diagnostic criteria, microbiology, antimicrobial management, and prevention. UTIs among patients with neurogenic bladder are associated with high morbidity and healthcare utilization. Risk factors for UTI among this population are: indwelling catheter, urinary stasis, high bladder pressure, and bladder stones. Their diagnosis is a major challenge as clinical signs are often non-specific and rare. A urinary sample should be analyzed in appropriate conditions before any antibiotic prescription. According to most guidelines, a bacterial threshold≥103CFU/ml associated with symptoms is acceptable to define UTI in patients with neurogenic bladder. The management of acute symptomatic UTI is not evidence-based. A management with a single agent and a short antibiotic treatment of 10 days or less seems effective. Antibiotic selection should be based on the patient's resistance patterns. Asymptomatic bacteriuria should not be treated to avoid the emergence of bacterial resistance. Regarding preventive measures, use of clean intermittent catheterization, intravesical botulinum toxin injection, and prevention using antibiotic cycling are effective. Bacterial interference is promising but randomized controlled trials are needed. Large ongoing cohorts and randomized controlled trials should soon provide more evidence-based data.

Identifiants

pubmed: 30885540
pii: S0399-077X(18)30613-9
doi: 10.1016/j.medmal.2019.02.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-504

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

A Dinh (A)

Service des maladies infectieuses et tropicales, hôpital R. Poincaré, hôpitaux universitaires Paris Île de France Ouest (HU-PIFO), AP-HP, UVSQ, 104, boulevard R.-Poincaré, 92380 Garches, France. Electronic address: aurelien.dinh@aphp.fr.

B Davido (B)

Service des maladies infectieuses et tropicales, hôpital R. Poincaré, hôpitaux universitaires Paris Île de France Ouest (HU-PIFO), AP-HP, UVSQ, 104, boulevard R.-Poincaré, 92380 Garches, France.

C Duran (C)

Service des maladies infectieuses et tropicales, hôpital R. Poincaré, hôpitaux universitaires Paris Île de France Ouest (HU-PIFO), AP-HP, UVSQ, 104, boulevard R.-Poincaré, 92380 Garches, France.

F Bouchand (F)

Pharmacie, hôpital R.-Poincaré, hôpitaux universitaires Paris Île de France Ouest, AP-HP, UVSQ, 92380 Garches, France.

J-L Gaillard (JL)

Laboratoire de microbiologie, hôpital R.-Poincaré, hôpitaux universitaires Paris Île de France Ouest, AP-HP, UVSQ, 92380 Garches, France.

A Even (A)

Service de neuro-urologie, hôpital R.-Poincaré, hôpitaux universitaires Paris Île de France Ouest, AP-HP, UVSQ, 92380 Garches, France.

P Denys (P)

Service de neuro-urologie, hôpital R.-Poincaré, hôpitaux universitaires Paris Île de France Ouest, AP-HP, UVSQ, 92380 Garches, France.

E Chartier-Kastler (E)

Service d'urologie, hôpital Pitié Salpêtrière, AP-HP, université Paris VI, 75013 Paris, France.

L Bernard (L)

Département des maladies infectieuses et tropicales, hôpital Bretonneau, université F.-Rabelais, 37000 Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH